TelePeptide review

TelePeptide sells mostly compounded GLP-1, but the peptide side is real: sermorelin and NAD⁺ are sold with their own routes, their own pages and their own full price ladders. What stands out is a pricing convention rather than a number. Its table shows sermorelin at $159 a month month-to-month, $109 on six months and $99 on annual, with the prepay totals printed in dollars — so the headline "$99" cannot be mistaken for what you will actually pay by the month. Every figure is stated to include the clinician evaluation, the prescription, the medication and shipping. What it will not tell you is the dose, the vial size or which pharmacy compounds it.

TelePeptide (TelePeptide LLC, trade name TelePep) is a US direct-pay telehealth practice operated under MD Integrations, P.C., a contracted medical group. Its menu spans compounded GLP-1 weight care (injectable and dissolvable-tablet semaglutide and tirzepatide, a semaglutide-plus-naltrexone combination and microdose combos), a longevity line covering NAD⁺ as a shot, nasal spray or sublingual tablet and sermorelin as a subcutaneous shot or sublingual troche, plus hair restoration. It states 503A compounding pharmacies without naming them, and it displays a LegitScript seal (ID 49966407) that links to LegitScript's own site.

Asynchronous. You complete an intake, a licensed US physician reviews it — the practice states typically within 24 hours — and if a prescription is clinically appropriate, medication ships from a licensed compounding pharmacy. Its homepage adds 24/7 messaging with a care team, regular check-ins and dosage adjustments as included at every tier, which is the kind of ongoing contact an injectable prescription should carry. State coverage is published rather than claimed: 48 US states and the District of Columbia, with Alaska and Mississippi named as excluded. Naming the exclusions is a small thing that saves a reader from completing a health questionnaire only to be turned away. The disclosure gaps are consistent and worth stating together: no compounding pharmacy is named, no individual clinician or medical director is published, and the founder appears by first name only. So you can verify the certification and the medical group but not the people or the facility, which is a middling position — better than an anonymous storefront, short of a service that names its 503A partner outright.

Well-presented pricing, and the reason is presentational rather than numeric. Sermorelin is $159 a month with no commitment, $654 up front for six months ($109 a month) or $1,188 for a year ($99 a month). NAD⁺ is $169 a month with no commitment, $834 for six months ($139 a month) or $1,548 for a year ($129 a month). Because the month-to-month rate and the prepay totals appear on the same table, the low figure cannot pass itself off as a monthly price, a common trap in this market. Every price is stated to include the clinician evaluation, the prescription, the medication and shipping, with the practice's own line being "no insurance, no surprise fees". Two questions remain open and both are worth asking before you order. Neither dose nor vial size appears beside any figure, so you cannot tell what a month contains. And labs are not mentioned in any plan, which for sermorelin means no baseline IGF-1 is included even though that is the measurement most likely to tell a clinician whether the drug is doing anything.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Its own FAQ states the position clearly and without softening: compounded preparations are not FDA-approved drugs and are not generic versions of branded products. Medication is stated to come from 503A compounding pharmacies, which are not named, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the two longevity products are not equal purchases. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone rather than supplying it, preserving a feedback loop that exogenous growth hormone overrides — a real, well-characterized mechanism whose long-term human outcome data thins out badly beyond short-term IGF-1 movement, and the sublingual troche route has less pharmacokinetic support than the injection. NAD⁺ is weaker still: the injected, intranasal and sublingual routes it sells have no controlled human outcome trials at all, while the forms with human trial data are the oral precursors NR and NMN, which raise a blood NAD⁺ level rather than demonstrate a clinical outcome. Individual results vary.